Pharmaceutical Policy Experts™

divider

340B Business Intelligence

Rx|X provides covered entities with a comprehensive analysis of the impact of various decisions related to starting-up or changes to their 340B program, including:

  • Calculation of potential savings for new participants, or for the addition of new locations
  • Evaluation on the pros/cons of contract pharmacy participation and contract terms
  • Review of WAC spend to identify expected and unexpected values, and how to address them
  • NDC-CDM crosswalk monitoring and maintenance for hospitals subject to the GPO prohibition
  • Orphan drug exclusion impact analysis
  • Diagnostics on IT feeds and program specifications to internal systems, split-billing vendors, and third party contract pharmacy administrators
  • Analysis on the impact of covered entity designation changes